Carna Biosciences, Inc. engages in the drug discovery business. It operates through the Drug Discovery Support and Drug Discovery and Development segments. The Drug Discovery Support segment provides drug discovery supporting products and services such as kinase protein, profiling services, assay development, crystallography, and cell-based assay services. The Drug Discovery and Development segment develops new medicines for the treatment of cancer and inflammatory diseases using the kinase drug discovery platform called QuickScout. The company was founded on April 10, 2003 and is headquartered in Kobe, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company